In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.
Commentary|Podcasts|December 11, 2025
Pharma Pulse: FDA Fast-Tracks Antibiotic Approval, as Protected EHR Time Combats Physician Burnout
Author(s)Nicholas Saraceno, Senior Editor
In today’s Pharma Pulse, Augmentin XR is the first drug approved under the FDA's new CNPV pilot program and much more.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.
- First, the FDA has opened the throttle on a new fast-track system. The agency just granted the
first approval under its new Commissioner's National Priority Voucher (CNPV) pilot program, greenlighting a US-manufactured version of the antibiotic, Augmentin XR, for the treatment of community-acquired pneumonia and acute bacterial sinusitis in both adult and pediatric patients, in just two months. The CNPV program is designed to reinforce national health and security priorities, specifically by promoting domestic manufacturing of essential medicines to stabilize the US drug supply chain and counter persistent shortages. - In other news, a
new study in JAMA Network Open found that by reserving just one dedicated appointment slot per half-day for physicians to focus on EHR tasks—like inbox messages and prior authorizations—the number of after-hours and weekend EHR work dropped sharply. This is a critical win for physician quality of life. Crucially, the key finding is that this reduction in burnout-inducing labor came with only a modest, short-term dip in overall productivity.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on
Advertisement
Related to this article
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.
HDA's Kala Shankle says a federal licensure baseline could bring real efficiency gains for wholesale distributors and 3PLs, but only if state requirements align and every stakeholder moves on the same timeline.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
Advertisement
Advertisement